# ATATcH Alternating Treatment Plans for Advanced Cancer

> **NCT05358548** · PHASE2 · RECRUITING · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 150 (estimated)

## Conditions studied

- Head and Neck Cancer
- Lung Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Pemetrexed
- **DRUG:** 5Fluorouracil
- **DRUG:** Carboplatin
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05358548
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-28
- **Primary completion:** 2027-05-01
- **Final completion:** 2028-05-01
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05358548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05358548, "ATATcH Alternating Treatment Plans for Advanced Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05358548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*